Ception Therapeutics
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$63.0m | Series C | ||
$14.7m | Series C | ||
$250m Valuation: $250m | Acquisition | ||
Total Funding | $77.7m |
Recent News about Ception Therapeutics
EditCeption Therapeutics operates in the biopharmaceutical sector, focusing on the monitoring and analysis of therapeutic effects of various medications. The company serves healthcare providers, researchers, and pharmaceutical companies by providing insights into the efficacy and safety of drugs such as Benazepril, Captopril, Procrit, Aranesp, Xanax, Tramadol, Propecia, and Kamagra. Operating in the global healthcare market, Ception Therapeutics employs a research-driven business model, generating revenue through partnerships, data licensing, and consultancy services. The company leverages its expertise in clinical research to offer high-quality, evidence-based information that aids in the development and optimization of therapeutic treatments. By continuously monitoring and evaluating drug performance, Ception Therapeutics aims to improve patient outcomes and support the advancement of medical science.
Keywords: biopharmaceutical, therapeutic effects, clinical research, drug monitoring, healthcare providers, pharmaceutical companies, medication efficacy, patient outcomes, data licensing, consultancy services.